MaSTherCell Revenue and Competitors

Gosselies, Belgium

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MaSTherCell's estimated annual revenue is currently $5M per year.(i)
  • MaSTherCell's estimated revenue per employee is $155,000

Employee Data

  • MaSTherCell has 32 Employees.(i)
  • MaSTherCell grew their employee count by -26% last year.

MaSTherCell's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M32-26%N/AN/A
#2
$510.1M109731%$2BN/A
#3
$13.6M8844%N/AN/A
#4
$12.2M790%N/AN/A
#5
$28.7M1855%N/AN/A
#6
$35.2M2278%N/AN/A
#7
$4M26-10%N/AN/A
#8
$10.9M7023%N/AN/A
#9
$10.4M6724%N/AN/A
#10
$6.2M4029%N/AN/A
Add Company

What Is MaSTherCell?

MaSTherCell Global is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. MaSTherCell Global Inc. is a gathering of MaSTherCell Belgium (a Belgium-based CDMO), Atvio Biotech Ltd. (an Israel-based CDMO), MaSTherCell Korea, (a Korea-based CDMO) and MaSTherCell USA (a CDMO based in Texas). At the heart of MaSTherCell is a team of more than 200 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell Global's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. For more information, visit www.masthercell.com.

keywords:N/A

N/A

Total Funding

32

Number of Employees

$5M

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.4M67-12%N/A
#2
$13.5M8728%N/A
#3
$14.9M9637%$83.7M
#4
$29.7M1101%N/A
#5
$28.7M1855%N/A